↓ Skip to main content

Dove Medical Press

Article Metrics

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells

Overview of attention for article published in International Journal of Nanomedicine, September 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
12 Mendeley
Title
Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
Published in
International Journal of Nanomedicine, September 2016
DOI 10.2147/ijn.s112560
Pubmed ID
Authors

Antonio Osuna, Fernando Rodríguez-Serrano, Nuria Mut-Salud, Teresa Cruz-Bustos, Mercedes Gomez-Samblas, Esther Carrasco, Jose Manuel Garrido, F. Javier López-Jaramillo, Francisco Santoyo-Gonzalez

Abstract

Around 20%-30% of breast cancers overexpress the proto-oncogene human epidermal growth receptor 2 (HER2), and they are characterized by being very invasive. Therefore, many current studies are focused on testing new therapies against tumors that overexpress this receptor. In particular, there exists major interest in new strategies to fight breast cancer resistant to trastuzumab (Tmab), a humanized antibody that binds specifically to HER2 interfering with its mitogenic signaling. Our team has previously developed immunostimulating complexes (ISCOMs) as nanocapsules functionalized with lipid vinyl sulfones, which can incorporate protein A and bind to G immunoglobulins that makes them very flexible nanocarriers. The aim of this in vitro study was to synthesize and evaluate a drug delivery system based on protein A-functionalized ISCOMs to target HER2-overexpressing cells. We describe the preparation of ISCOMs, the loading with the drugs doxorubicin and paclitaxel, the binding of ISCOMs to alkyl vinyl sulfone-protein A, the coupling of Tmab, and the evaluation in both HER2-overexpressing breast cancer cells (HCC1954) and non-overexpressing cells (MCF-7) by flow cytometry and fluorescence microscopy. Results show that the uptake is dependent on the level of overexpression of HER2, and the analysis of the cell viability reveals that targeted drugs are selective toward HCC1954, whereas MCF-7 cells remain unaffected. Protein A-functionalized ISCOMs are versatile carriers that can be coupled to antibodies that act as targeting agents to deliver drugs. When coupling to Tmab and loading with paclitaxel or doxorubicin, they become efficient vehicles for the selective delivery of the drug to Tmab-resistant HER2-overexpressing breast cancer cells. These nanoparticles may pave the way for the development of novel therapies for poor prognosis resistant patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 8%
Unknown 11 92%

Demographic breakdown

Readers by professional status Count As %
Other 3 25%
Student > Master 3 25%
Student > Bachelor 2 17%
Professor 1 8%
Student > Ph. D. Student 1 8%
Other 1 8%
Unknown 1 8%
Readers by discipline Count As %
Medicine and Dentistry 3 25%
Biochemistry, Genetics and Molecular Biology 2 17%
Immunology and Microbiology 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Chemistry 1 8%
Other 2 17%
Unknown 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2016.
All research outputs
#6,381,749
of 8,409,255 outputs
Outputs from International Journal of Nanomedicine
#1,394
of 1,840 outputs
Outputs of similar age
#178,437
of 253,630 outputs
Outputs of similar age from International Journal of Nanomedicine
#107
of 121 outputs
Altmetric has tracked 8,409,255 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,840 research outputs from this source. They receive a mean Attention Score of 2.5. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,630 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.